ICCC ImmuCell Corporation logo

ICCC ImmuCell Corporation

Healthcare
$10.12+1.10%ClosedMarket Cap: $91.6M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

PEG

P/B

3.14

P/S

3.06

EV/EBITDA

42.37

DCF Value

$-13.90

FCF Yield

3.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

42.6%

Operating Margin

8.4%

Net Margin

-1.8%

ROE

-1.9%

ROA

-1.2%

ROIC

6.0%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$10.4M$1.9M$
Q4 null$7.6M$-2.8M$
FY null$27.6M$-1.0M$
Q3 null$5.5M$-139.7K$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All
Guillemette Gillesdirector
SellThu Apr 23
DiMarco Anthonydirector
SellThu Apr 23
Wainman Paul Rdirector
SellThu Apr 16
Turner Kathy Vdirector
SellThu Apr 16
Tomsche David Scottdirector
SellThu Apr 16

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

0.50

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Peers